UNITED THERAPEUTICS CorpUTHREarnings & Financial Report
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; ...
UTHR Q4 2025 Key Financial Metrics
营收
$790.2M
毛利润
$686.8M
营业利润
$356.7M
净利润
$364.3M
毛利率
86.9%
营业利润率
45.1%
净利率
46.1%
同比增长
7.4%
EPS
$7.66
资金流向
UNITED THERAPEUTICS Corp Q4 2025 Financial Summary
UNITED THERAPEUTICS Corp reported revenue of $790.2M (up 7.4% YoY) for Q4 2025, with a net profit of $364.3M (up 20.9% YoY) (46.1% margin). Cost of goods sold was $103.4M, operating expenses totaled $330.1M.
Key Financial Metrics
| Total Revenue | $790.2M |
|---|---|
| Net Profit | $364.3M |
| Gross Margin | 86.9% |
| Operating Margin | 45.1% |
| Report Period | Q4 2025 |
Revenue Breakdown
UNITED THERAPEUTICS Corp Q4 2025 revenue of $790.2M breaks down across 7 segments, led by Tyvaso DPI at $338.6M (42.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Tyvaso DPI | $338.6M | 42.8% |
| Remodulin | $128.0M | 16.2% |
| Nebulized Tyvaso | $125.7M | 15.9% |
| Orenitram | $121.2M | 15.3% |
| Unituxin | $62.3M | 7.9% |
| Adcirca | $7.8M | 1.0% |
| Other | $6.6M | 0.8% |
UNITED THERAPEUTICS Corp Revenue by Segment — Quarterly Trend
UNITED THERAPEUTICS Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Tyvaso DPI and Remodulin) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Tyvaso DPI | $338.6M | $336.2M | $315.2M | $302.5M |
| Remodulin | $128.0M | $125.9M | $134.7M | $138.2M |
| Nebulized Tyvaso | $125.7M | $141.8M | $154.4M | $163.8M |
| Orenitram | $121.2M | $131.1M | $123.9M | $120.7M |
| Unituxin | $62.3M | $47.9M | $58.4M | $58.2M |
UNITED THERAPEUTICS Corp Annual Revenue by Year
UNITED THERAPEUTICS Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.2B). Click any linked year to see what changed vs the prior 10-K.
UNITED THERAPEUTICS Corp Quarterly Revenue & Net Profit History
UNITED THERAPEUTICS Corp quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $790.2M | +7.4% | $364.3M | 46.1% |
| Q3 2025 | $799.5M | +6.8% | $338.7M | 42.4% |
| Q2 2025 | $798.6M | +11.7% | $309.5M | 38.8% |
| Q1 2025 | $794.4M | +17.2% | $322.2M | 40.6% |
| Q4 2024 | $735.9M | +19.7% | $301.3M | 40.9% |
| Q3 2024 | $748.9M | +22.9% | $309.1M | 41.3% |
| Q2 2024 | $714.9M | +19.8% | $278.1M | 38.9% |
| Q1 2024 | $677.7M | +33.7% | $306.6M | 45.2% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $677.7M | $714.9M | $748.9M | $735.9M | $794.4M | $798.6M | $799.5M | $790.2M |
| 同比增长 | 33.7% | 19.8% | 22.9% | 19.7% | 17.2% | 11.7% | 6.8% | 7.4% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $6.50B | $6.72B | $7.12B | $7.36B | $7.74B | $7.91B | $7.35B | $7.88B |
| 总负债 | $1.16B | $1.03B | $1.02B | $920.0M | $936.7M | $734.4M | $760.9M | $783.8M |
| 股东权益 | $5.34B | $5.70B | $6.10B | $6.44B | $6.81B | $7.17B | $6.59B | $7.10B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $376.5M | $232.2M | $377.2M | $341.2M | $461.2M | $191.7M | $562.1M | $346.2M |